For further information, please refer Smaller and Travel Sizes.

Note: Travel sizes of the rosacea sunscreens are not made.

A classification system for rosacea identifies 4 subtypes (ie, erythematotelangiectatic, papulopustular, phymatous, and ocular), which may help guide therapeutic decision making.

Until recently, the pathophysiology of acne rosacea has been poorly understood and limited to descriptions of factors that exacerbate or improve this disorder.

Recent molecular studies suggest that an altered innate immune response is involved in the pathogenesis of the vascular and inflammatory disease seen in patients with rosacea.

These findings may help explain the benefits of current treatments and suggest new therapeutic strategies helpful for alleviating this disease.

The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.

Standard topical treatment agents include metronidazole, azelaic acid, and sodium sulfacetamide-sulfur.

Second-line therapies include benzoyl peroxide, clindamycin, calcineurin inhibitors, and permethrin. There are also various systemic therapy options.

An extensive list of conditions and of the types of iron association were published in early 2008.

Within the subsequent year, four additional disorders have been recognized to be enhanced by iron: aging muscle atrophy, viral replication, rosacea and pulmonary alveolar proteinosis.

This paper adds new data and emphasis on these disorders as entities associated with increased iron load and toxicity.